GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » 3-Year EPS without NRI Growth Rate

Clal Biotechnology Industries (XTAE:CBI) 3-Year EPS without NRI Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries 3-Year EPS without NRI Growth Rate?

Clal Biotechnology Industries's EPS without NRI for the three months ended in Dec. 2023 was ₪0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Clal Biotechnology Industries was 54.50% per year. The lowest was -43.90% per year. And the median was 9.30% per year.


Competitive Comparison of Clal Biotechnology Industries's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Clal Biotechnology Industries's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clal Biotechnology Industries's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Clal Biotechnology Industries's 3-Year EPS without NRI Growth Rate falls into.



Clal Biotechnology Industries 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Clal Biotechnology Industries  (XTAE:CBI) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Clal Biotechnology Industries 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries (XTAE:CBI) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries (XTAE:CBI) Headlines

From GuruFocus

CB&I Announces Storage Award for Export Facility in Canada

By PRNewswire PRNewswire 04-26-2018

CB&I Announces Novolen Technology Award in China

By PRNewswire PRNewswire 04-03-2018

Van Den Berg Reduces Position in 5-Star Company

By Kyle Ferguson Kyle Ferguson 01-25-2016

This Warren Buffett Bargain Stock Is Good For A Double

By Jonathan Poland Jonathan Poland 05-27-2015

Van Den Berg Almost Sells Out 4 Stakes in 1st Quarter

By David Goodloe David Goodloe 04-20-2016

Dollar Cost Average on CBI

By Jonathan Poland Jonathan Poland 08-17-2017

CB&I To Report First Quarter 2018 Financial Results on April 23

By PRNewswire PRNewswire 04-09-2018